Active surveillance in low-risk disease tied to 2.4 percent cancer-specific death rate over 10 years-- Jeff Muise
Monday, June 21, 2010 (Last Updated: 06/22/2010)
MONDAY, June 21 (HealthDay News) -- For patients with prostate cancer that has a low risk of progression, active surveillance is associated with a low death rate, suggesting that it may be a sufficient management approach, according to research published online June 18 in the Journal of the National Cancer Institute.
Pär Stattin, M.D., of the Umeå University Hospital in Sweden, and colleagues extracted data from Sweden's National Prostate Cancer Registry 1997 to 2002 on 6,849 patients with localized prostate cancer, aged 70 years or younger, who had low to intermediate risk of progression and were managed using one of three approaches: active surveillance and watchful waiting, radical prostatectomy, or radiation therapy.
After 10 years of follow-up, the researchers found that cumulative prostate cancer-specific death rates overall were 2.4 percent for those in the prostatectomy group, 3.6 percent for those in the surveillance group, and 3.3 percent for those in the radiation-therapy group. For those with low-risk disease, the rates were 0.4, 2.4, and 1.8 percent, respectively. The 10-year risk of dying from competing causes, however, was 19.2 percent in the surveillance group, 8.5 percent in the prostatectomy group, and 14.2 percent in the radiation-therapy group.
"A 10-year prostate cancer-specific mortality of 2.4 percent among patients with low-risk prostate cancer in the surveillance group indicates that surveillance may be a suitable treatment option for many patients with low-risk disease," the authors write.
Hematology & Oncology
Copyright © 2010 HealthDay. All rights reserved.
June 11, 2015
November 20, 2015